Publications
Publications
- August 2001
- HBS Case Collection
Scios, Inc.
Abstract
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process.
Keywords
Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States
Citation
Herzlinger, Regina E. "Scios, Inc." Harvard Business School Case 302-034, August 2001.